查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1974443

人工智慧市场分析及预测（至2035年）：预测药物反应建模－按类型、产品类型、服务、技术、组件、应用、最终用户、功能、部署模式和解决方案划分

AI for Predictive Drug Response Modeling Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, End User, Functionality, Deployment, Solutions
出版日期: | 出版商: Global Insight Services | 英文 369 Pages | 商品交期: 3-5个工作天内

价格
简介目录

用于预测药物反应建模的人工智慧市场预计将从2024年的23亿美元成长到2034年的36亿美元，复合年增长率约为4.6%。该市场涵盖利用人工智慧预测患者药物反应并改善精准医疗的技术。它将机器学习演算法与生物医学数据相结合，以优化药物疗效和安全性。对个人化医疗日益增长的需求以及人工智慧驱动的分析技术的进步正在推动计算生物学和医疗资讯学领域的成长和创新。

全球人工智慧药物反应预测建模市场正受到关税、地缘政治风险和不断变化的供应链趋势等多重因素的复杂影响。在日本和韩国，对人工智慧相关进口产品征收关税促使两国战略转向加强国内研发能力，并推动人工智慧驱动的医疗健康解决方案创新。为因应出口限制，中国大力推动人工智慧技术自主研发，并投入大量资金发展国内人工智慧技术。台湾作为半导体强国，面临可能削弱其市场关键地位的地缘政治不确定性。在全球范围内，受个人化医疗和先进分析技术需求的驱动，母市场正经历强劲成长。到2035年，市场扩张将取决于稳健的供应链和战略伙伴关係，而中东衝突可能会影响能源价格和製造成本。

市场区隔
类型 机器学习、深度学习、自然语言处理
产品 软体平台、人工智慧演算法、资料管理工具
服务 咨询、整合和实施、支援和维护、培训和教育
科技 云端部署、本地部署、混合部署
成分 硬体、软体、服务
应用 肿瘤学、心臟病学、神经病学、感染疾病、免疫学
最终用户 製药公司、生技公司、研究机构、医疗保健机构
功能 预测分析、资料探勘、模拟
实施表格 大型企业、中小企业
解决方案 客製化解决方案，标准解决方案

受个人化医疗和数据分析技术进步的推动，用于预测药物反应建模的人工智慧市场正经历强劲成长。其中，软体领域成长最为迅猛，这主要得益于机器学习演算法和人工智慧平台的集成，从而提高了预测精度。特别是，人工智慧驱动的分析工具和机器学习框架处于领先地位，透过个人化治疗方案，帮助改善患者预后。

硬体领域位居第二，专注于人工智慧优化处理器和资料储存解决方案，以支援复杂的运算需求。这些技术对于处理预测建模所需的海量资料集至关重要。此外，儘管云端解决方案因其扩充性和成本效益而日益普及，但本地部署系统对于资料敏感型应用仍然不可或缺。人工智慧与生物技术的融合不断开启新的可能性，推动创新并加速市场发展。製药公司与人工智慧技术供应商之间日益密切的合作进一步促进了这一趋势。

用于预测药物反应建模的人工智慧市场呈现出动态的市场环境，包括市场份额分布、定价策略和新产品推出。各公司对客户需求和竞争压力有着敏锐的洞察力，并积极采用创新的定价模式来扩大市场占有率。科技的快速进步和对个人化医疗解决方案日益增长的需求，推动了新产品的涌现。这为创新创造了有利的环境，各公司竞相透过不断改进产品线来超越竞争对手。

该市场竞争异常激烈，主要企业透过策略联盟和收购争夺主导。与行业巨头相比，规模较小的公司正利用其专业优势和灵活应变能力，建立独特的市场地位。监管的影响至关重要，北美和欧洲严格的政策塑造了竞争格局。这些法规在确保高标准的同时，也对新进入者构成了障碍。市场分析显示，监管协调的趋势正在显现，预计将提高营运效率，并促进跨境创新。

主要趋势和驱动因素：

人工智慧和机器学习技术的进步推动了药物反应预测建模领域的市场快速成长。运算能力的提升和先进演算法的出现，使得药物反应预测更加精准，并显着缩短了研发週期。随着製药公司寻求高效且经济的解决方案，将人工智慧融入药物研发流程变得至关重要。

一个关键趋势是个人化医疗的兴起，它利用人工智慧根据个人基因谱客製化治疗方案。基因组学和生物技术领域投资的增加推动了这一趋势的发展。监管机构正积极应对这些技术进步，提供既能促进创新又能确保病人安全的框架。

此外，科技公司与医疗服务提供者之间的合作正在推动创新人工智慧平台的发展。这些伙伴关係旨在提高预测准确性并改善患者疗效。随着药物研发领域对预测建模的需求持续成长，能够提供扩充性且稳健的人工智慧解决方案的公司将迎来许多机会。

限制与挑战：

用于预测药物反应建模的人工智慧市场目前面临许多重大限制和挑战。其中一项主要挑战是监管环境的复杂性，阻碍了人工智慧技术快速融入医疗保健系统。遵守各种国际标准也增加了难度，减缓了市场渗透速度。此外，精通人工智慧和药理学的专业人才严重短缺，也成为创新和应用的瓶颈。

资料隐私问题也是一大障碍。如何在利用人工智慧进行预测建模的同时确保敏感医疗数据的机密性，仍然是一项重大挑战，而世界各地不同的资料保护条例更使这项挑战雪上加霜。

此外，人工智慧技术实施成本高昂，限制了其广泛应用，尤其是在中小型製药公司和研究机构。这些成本不仅包括初始投资，还包括持续的维护和更新费用。

互通性也是一个重大挑战：将人工智慧系统整合到现有的医疗保健基础设施中常常会遇到技术难题，阻碍无缝运作。

最后，医疗专业人员的怀疑态度也是市场面临的一大挑战。他们可能不愿相信人工智慧的预测结果，而更倾向于传统方法。因此，建立人们对人工智慧准确性和可靠性的信心，对于人工智慧的广泛接受和应用至关重要。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制因素
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 机器学习
    • 深度学习
    • 自然语言处理
  • 市场规模及预测：依产品划分
    • 软体平台
    • 人工智慧演算法
    • 资料管理工具
  • 市场规模及预测：依服务划分
    • 咨询
    • 整合与实施
    • 支援与维护
    • 培训和教育
  • 市场规模及预测：依技术划分
    • 基于云端的
    • 本地部署
    • 杂交种
  • 市场规模及预测：依组件划分
    • 硬体
    • 软体
    • 服务
  • 市场规模及预测：依应用领域划分
    • 肿瘤学
    • 心臟病学
    • 神经病学
    • 感染疾病
    • 免疫学
  • 市场规模及预测：依最终用户划分
    • 製药公司
    • 生技公司
    • 研究所
    • 医疗保健提供者
  • 市场规模及预测：依功能划分
    • 预测分析
    • 资料探勘
    • 模拟
  • 市场规模及预测：依发展状况
    • 大公司
    • 小型企业
  • 市场规模及预测：按解决方案划分
    • 客製化解决方案
    • 标准溶液

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 供需差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章：公司简介

  • Atomwise
  • Exscientia
  • Benevolent AI
  • Insilico Medicine
  • Recursion Pharmaceuticals
  • Numerate
  • Cyclica
  • Deep Genomics
  • Berg Health
  • GNS Healthcare
  • Bio Symetrics
  • Owkin
  • Standigm
  • Xtal Pi
  • Two XAR
  • Aria Pharmaceuticals
  • Aiforia Technologies
  • Verge Genomics
  • Aigenpulse
  • Quibim

第九章 关于我们

简介目录
Product Code: GIS32706

AI for Predictive Drug Response Modeling Market is anticipated to expand from $2.3 Billion in 2024 to $3.6 Billion by 2034, growing at a CAGR of approximately 4.6%. The AI for Predictive Drug Response Modeling Market encompasses technologies that leverage artificial intelligence to forecast patient responses to pharmaceuticals, enhancing precision medicine. This market integrates machine learning algorithms with biomedical data, aiming to optimize drug efficacy and safety. Increasing demand for personalized treatment and advancements in AI-driven analytics are propelling growth, fostering innovations in computational biology and healthcare informatics.

The global AI for Predictive Drug Response Modeling Market is intricately influenced by tariffs, geopolitical risks, and evolving supply chain trends. In Japan and South Korea, the imposition of tariffs on AI-related imports is prompting a strategic pivot towards enhancing local R&D capabilities and fostering innovation in AI-driven healthcare solutions. China's response to export restrictions involves a robust push towards self-reliance, investing heavily in domestic AI advancements. Taiwan, while a semiconductor powerhouse, faces geopolitical uncertainties that could disrupt its pivotal role in the market. Globally, the parent market is experiencing robust growth, driven by the demand for personalized medicine and advanced analytics. By 2035, the market's expansion will hinge on resilient supply chains and strategic alliances, with Middle East conflicts potentially affecting energy prices and manufacturing costs.

Market Segmentation
TypeMachine Learning, Deep Learning, Natural Language Processing
ProductSoftware Platforms, AI Algorithms, Data Management Tools
ServicesConsulting, Integration and Implementation, Support and Maintenance, Training and Education
TechnologyCloud-based, On-premise, Hybrid
ComponentHardware, Software, Services
ApplicationOncology, Cardiology, Neurology, Infectious Diseases, Immunology
End UserPharmaceutical Companies, Biotechnology Firms, Research Institutes, Healthcare Providers
FunctionalityPredictive Analytics, Data Mining, Simulation
DeploymentLarge Enterprises, SMEs
SolutionsCustomized Solutions, Standard Solutions

The AI for Predictive Drug Response Modeling Market is experiencing robust growth, propelled by advancements in personalized medicine and data analytics. Within this market, the software segment emerges as the top-performing category, driven by the integration of machine learning algorithms and AI platforms that enhance predictive accuracy. Particularly, AI-driven analytics tools and machine learning frameworks are at the forefront, facilitating better patient outcomes through tailored treatment plans.

The second highest performing segment is hardware, with a focus on AI-optimized processors and data storage solutions that support complex computational needs. These technologies are pivotal in processing vast datasets required for predictive modeling. Additionally, cloud-based solutions are increasingly favored for their scalability and cost-effectiveness, although on-premise systems remain crucial for data-sensitive applications. The convergence of AI with biotechnology continues to unlock new opportunities, fostering innovation and driving market momentum. Enhanced collaboration between pharmaceutical companies and AI technology providers further accelerates this dynamic landscape.

The AI for Predictive Drug Response Modeling market is characterized by a dynamic landscape of market share distribution, pricing strategies, and new product launches. Companies are increasingly adopting innovative pricing models to capture greater market share, reflecting a keen understanding of customer needs and competitive pressures. The market is witnessing a surge in new product introductions, driven by rapid technological advancements and a growing demand for personalized medicine solutions. This has fostered an environment ripe for innovation, with firms striving to outpace competitors by continuously evolving their product offerings.

Competition in this market is fierce, with key players vying for dominance through strategic partnerships and acquisitions. Benchmarking against industry giants, smaller firms leverage niche expertise and agility to carve out market niches. Regulatory influences play a pivotal role, with stringent policies in North America and Europe shaping the competitive landscape. These regulations ensure high standards, yet also pose barriers to entry for new entrants. The market analysis reveals a trend towards increased regulatory harmonization, which could streamline operations and foster innovation across borders.

Geographical Overview:

The AI for Predictive Drug Response Modeling market is witnessing substantial growth across diverse regions. North America leads the charge, benefiting from advanced healthcare infrastructure and significant investments in AI research. The region's robust pharmaceutical sector is increasingly integrating AI to enhance drug efficacy and patient outcomes. Europe is not far behind, with its strong focus on precision medicine and AI-driven healthcare innovations.

The continent's regulatory frameworks support AI adoption, fostering a conducive environment for market expansion. Asia Pacific emerges as a promising growth pocket, driven by rapid technological advancements and a burgeoning pharmaceutical industry. Countries like China and India are at the forefront, investing heavily in AI to revolutionize drug development processes. Latin America and the Middle East & Africa are also gaining traction, with Brazil and the UAE emerging as key players. These regions are recognizing AI's potential to transform healthcare, paving the way for future growth.

Recent Developments:

In recent months, the AI for Predictive Drug Response Modeling Market has been marked by pivotal developments. Pfizer announced a collaboration with IBM to enhance their predictive modeling capabilities, leveraging AI to improve drug response predictions in clinical trials. This partnership aims to accelerate drug development timelines and reduce costs by utilizing advanced AI algorithms.

Roche has taken a strategic step by acquiring a minority stake in a promising AI startup specializing in predictive drug response. This investment underscores Roche's commitment to integrating cutting-edge AI technologies into their drug development processes, potentially revolutionizing personalized medicine.

In a significant regulatory update, the FDA has issued new guidelines for the integration of AI in predictive drug response modeling. These guidelines are designed to ensure the safety and efficacy of AI-driven predictions, providing a framework for companies to innovate while maintaining compliance.

AstraZeneca has launched an innovative AI platform designed to predict patient responses to cancer treatments. This platform utilizes machine learning to analyze vast datasets, offering oncologists valuable insights into treatment efficacy and patient outcomes.

Novartis has announced a joint venture with a leading tech company to develop AI-driven predictive models for rare diseases. This collaboration aims to address the unique challenges of rare disease drug development by harnessing AI's potential to predict patient responses more accurately.

Key Trends and Drivers:

The AI for Predictive Drug Response Modeling Market is expanding rapidly, driven by advancements in AI and machine learning. Enhanced computational power and sophisticated algorithms are enabling precise predictions of drug responses, significantly reducing research timelines. The integration of AI into drug discovery processes is becoming indispensable, as pharmaceutical companies strive for more efficient and cost-effective solutions.

Key trends include the growing adoption of personalized medicine, which leverages AI to tailor treatments to individual genetic profiles. This trend is further fueled by increasing investments in genomics and biotechnologies. Regulatory bodies are also adapting to these technological advancements, providing frameworks that encourage innovation while ensuring patient safety.

Furthermore, the collaboration between tech companies and healthcare providers is fostering the development of innovative AI-driven platforms. These partnerships aim to enhance predictive accuracy and improve patient outcomes. Opportunities abound for companies that can offer scalable, robust AI solutions, as the demand for predictive modeling in drug development continues to rise.

Restraints and Challenges:

The AI for Predictive Drug Response Modeling Market is currently grappling with several significant restraints and challenges. A primary challenge is the regulatory landscape's complexity, which hinders the swift integration of AI technologies into healthcare systems. Compliance with diverse international standards adds layers of difficulty, slowing market penetration. Furthermore, there is a notable shortage of skilled professionals adept in both AI and pharmacology, creating a bottleneck for innovation and implementation.

Data privacy concerns present another formidable barrier. Ensuring the confidentiality of sensitive medical data while leveraging AI for predictive modeling remains a critical issue. This challenge is exacerbated by varying global data protection regulations.

Moreover, the high cost of AI technology deployment limits its adoption, particularly among smaller pharmaceutical firms and research institutions. These costs include not only initial investments but also ongoing maintenance and updates.

Interoperability issues also pose a significant challenge. Integrating AI systems with existing healthcare infrastructure is often fraught with technical difficulties, impeding seamless operation.

Lastly, the market faces skepticism from healthcare professionals who may be reluctant to trust AI-generated predictions over traditional methods. Building confidence in AI's accuracy and reliability is essential for broader acceptance and utilization.

Key Companies:

Atomwise, Exscientia, Benevolent AI, Insilico Medicine, Recursion Pharmaceuticals, Numerate, Cyclica, Deep Genomics, Berg Health, GNS Healthcare, Bio Symetrics, Owkin, Standigm, Xtal Pi, Two XAR, Aria Pharmaceuticals, Aiforia Technologies, Verge Genomics, Aigenpulse, Quibim

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Component
  • 2.6 Key Market Highlights by Application
  • 2.7 Key Market Highlights by End User
  • 2.8 Key Market Highlights by Functionality
  • 2.9 Key Market Highlights by Deployment
  • 2.10 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Machine Learning
    • 4.1.2 Deep Learning
    • 4.1.3 Natural Language Processing
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Software Platforms
    • 4.2.2 AI Algorithms
    • 4.2.3 Data Management Tools
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Consulting
    • 4.3.2 Integration and Implementation
    • 4.3.3 Support and Maintenance
    • 4.3.4 Training and Education
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Cloud-based
    • 4.4.2 On-premise
    • 4.4.3 Hybrid
  • 4.5 Market Size & Forecast by Component (2020-2035)
    • 4.5.1 Hardware
    • 4.5.2 Software
    • 4.5.3 Services
  • 4.6 Market Size & Forecast by Application (2020-2035)
    • 4.6.1 Oncology
    • 4.6.2 Cardiology
    • 4.6.3 Neurology
    • 4.6.4 Infectious Diseases
    • 4.6.5 Immunology
  • 4.7 Market Size & Forecast by End User (2020-2035)
    • 4.7.1 Pharmaceutical Companies
    • 4.7.2 Biotechnology Firms
    • 4.7.3 Research Institutes
    • 4.7.4 Healthcare Providers
  • 4.8 Market Size & Forecast by Functionality (2020-2035)
    • 4.8.1 Predictive Analytics
    • 4.8.2 Data Mining
    • 4.8.3 Simulation
  • 4.9 Market Size & Forecast by Deployment (2020-2035)
    • 4.9.1 Large Enterprises
    • 4.9.2 SMEs
  • 4.10 Market Size & Forecast by Solutions (2020-2035)
    • 4.10.1 Customized Solutions
    • 4.10.2 Standard Solutions

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Component
      • 5.2.1.6 Application
      • 5.2.1.7 End User
      • 5.2.1.8 Functionality
      • 5.2.1.9 Deployment
      • 5.2.1.10 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Component
      • 5.2.2.6 Application
      • 5.2.2.7 End User
      • 5.2.2.8 Functionality
      • 5.2.2.9 Deployment
      • 5.2.2.10 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Component
      • 5.2.3.6 Application
      • 5.2.3.7 End User
      • 5.2.3.8 Functionality
      • 5.2.3.9 Deployment
      • 5.2.3.10 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Component
      • 5.3.1.6 Application
      • 5.3.1.7 End User
      • 5.3.1.8 Functionality
      • 5.3.1.9 Deployment
      • 5.3.1.10 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Component
      • 5.3.2.6 Application
      • 5.3.2.7 End User
      • 5.3.2.8 Functionality
      • 5.3.2.9 Deployment
      • 5.3.2.10 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Component
      • 5.3.3.6 Application
      • 5.3.3.7 End User
      • 5.3.3.8 Functionality
      • 5.3.3.9 Deployment
      • 5.3.3.10 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Component
      • 5.4.1.6 Application
      • 5.4.1.7 End User
      • 5.4.1.8 Functionality
      • 5.4.1.9 Deployment
      • 5.4.1.10 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Component
      • 5.4.2.6 Application
      • 5.4.2.7 End User
      • 5.4.2.8 Functionality
      • 5.4.2.9 Deployment
      • 5.4.2.10 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Component
      • 5.4.3.6 Application
      • 5.4.3.7 End User
      • 5.4.3.8 Functionality
      • 5.4.3.9 Deployment
      • 5.4.3.10 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Component
      • 5.4.4.6 Application
      • 5.4.4.7 End User
      • 5.4.4.8 Functionality
      • 5.4.4.9 Deployment
      • 5.4.4.10 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Component
      • 5.4.5.6 Application
      • 5.4.5.7 End User
      • 5.4.5.8 Functionality
      • 5.4.5.9 Deployment
      • 5.4.5.10 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Component
      • 5.4.6.6 Application
      • 5.4.6.7 End User
      • 5.4.6.8 Functionality
      • 5.4.6.9 Deployment
      • 5.4.6.10 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Component
      • 5.4.7.6 Application
      • 5.4.7.7 End User
      • 5.4.7.8 Functionality
      • 5.4.7.9 Deployment
      • 5.4.7.10 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Component
      • 5.5.1.6 Application
      • 5.5.1.7 End User
      • 5.5.1.8 Functionality
      • 5.5.1.9 Deployment
      • 5.5.1.10 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Component
      • 5.5.2.6 Application
      • 5.5.2.7 End User
      • 5.5.2.8 Functionality
      • 5.5.2.9 Deployment
      • 5.5.2.10 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Component
      • 5.5.3.6 Application
      • 5.5.3.7 End User
      • 5.5.3.8 Functionality
      • 5.5.3.9 Deployment
      • 5.5.3.10 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Component
      • 5.5.4.6 Application
      • 5.5.4.7 End User
      • 5.5.4.8 Functionality
      • 5.5.4.9 Deployment
      • 5.5.4.10 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Component
      • 5.5.5.6 Application
      • 5.5.5.7 End User
      • 5.5.5.8 Functionality
      • 5.5.5.9 Deployment
      • 5.5.5.10 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Component
      • 5.5.6.6 Application
      • 5.5.6.7 End User
      • 5.5.6.8 Functionality
      • 5.5.6.9 Deployment
      • 5.5.6.10 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Component
      • 5.6.1.6 Application
      • 5.6.1.7 End User
      • 5.6.1.8 Functionality
      • 5.6.1.9 Deployment
      • 5.6.1.10 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Component
      • 5.6.2.6 Application
      • 5.6.2.7 End User
      • 5.6.2.8 Functionality
      • 5.6.2.9 Deployment
      • 5.6.2.10 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Component
      • 5.6.3.6 Application
      • 5.6.3.7 End User
      • 5.6.3.8 Functionality
      • 5.6.3.9 Deployment
      • 5.6.3.10 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Component
      • 5.6.4.6 Application
      • 5.6.4.7 End User
      • 5.6.4.8 Functionality
      • 5.6.4.9 Deployment
      • 5.6.4.10 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Component
      • 5.6.5.6 Application
      • 5.6.5.7 End User
      • 5.6.5.8 Functionality
      • 5.6.5.9 Deployment
      • 5.6.5.10 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Atomwise
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Exscientia
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Benevolent AI
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Insilico Medicine
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Recursion Pharmaceuticals
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Numerate
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Cyclica
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Deep Genomics
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Berg Health
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 GNS Healthcare
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Bio Symetrics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Owkin
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Standigm
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Xtal Pi
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Two XAR
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Aria Pharmaceuticals
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Aiforia Technologies
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Verge Genomics
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Aigenpulse
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Quibim
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us